This study is testing a drug called lisaftoclax for people with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL). You may be able to join if you are 18 to 85 years old and your CLL/SLL has come back or not responded to at least one previous treatment. The main goals are to find out how safe lisaftoclax is, what side effects it might cause, and the highest dose that can be given safely. The study will look at lisaftoclax by itself and in combination with other treatments like rituximab or acalabrutinib. The study plans to enroll 144 participants. The current status of the study is unclear.

Study design

This is an interventional study with a planned enrollment of 144 participants. It will involve a ramp-up period, dose escalation, and dose expansion for lisaftoclax as a single agent and in combination with other drugs.

What's involved

You would take lisaftoclax daily, starting with a lower dose that gradually increases over several days. The ramp-up period will vary from 3 to 8 days depending on your assigned maximum dose.

Compensation

Not stated in the trial record.

Follow-up

The primary safety endpoints, dose-limiting toxicity (DLT) and maximally tolerated dose (MTD), will be measured at 42 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.